STK11 Loss

CI-VAR-00002474Explore in graph →CIViC 485

Curated evidence

Evidence by cancer (6 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–6 of 6 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma2
STK11 Loss	Docetaxel + SelumetinibCombination	Predictive	D	Supports Resistance	3	accepted	EID1144 A clinical trial comparing selumetinib and docetaxel vs. docetaxel and placebo in KRAS mutant NSCLC was recapitulated in mice. Tumors were induced in lung epithelium by nasal instillation of CRE-beari… (full text at CIViC) PMID 22425996 · Chen et al., 2012 · Open in CIViC	civic
STK11 Loss	Everolimus + SirolimusSubstitutes	Predictive	D	Does Not Support Sensitivity Response	3	accepted	EID1620 Preclinical study in 5 NSCLC cell lines. Two LKB1 (STK11) mutant cell lines had higher basal levels of mTOR activity (pS6K and p4EBP1 levels) but were not more sensitive to mTOR inhibitors (everolimus… (full text at CIViC)

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Pancreatic Ductal Adenocarcinoma1
STK11 Loss	Roflumilast	Predictive	D	Supports Sensitivity Response	2	accepted	EID12555 In a preclinical study using STK11/LKB1-deficient pancreatic ductal adenocarcinoma (PDAC) cell lines (TB 32047, PANC-1, SUIT2, SU86.86, KPC792) and C57BL/6 orthotopic mouse models (n = 5 per group), t… (full text at CIViC) PMID 38461159 · Zhang et al., 2024 · Open in CIViC	civic

Peutz-Jeghers Syndrome3unmapped disease
STK11 Loss	(predisposing)	Predisposing	B	Supports Predisposition	3	accepted	EID1737 In a series of 33 patients with Peutz-Jeghers Syndrome, 17 mutations in STK11/LKB1 were observed in exons 1-8 (none in exon 9). 11 of these mutations were predicted to be truncating. These mutations o… (full text at CIViC) PMID 12865922 · Lim et al., 2003 · Open in CIViC	civic
STK11 Loss	Sirolimus	Predictive	D	Supports Sensitivity Response	1	accepted	EID1618 Preclinical study in a mouse model of Peutz-Jeghers syndrome. Heterozygous Lkb1 (STK11) knockout mice were generated and treated with rapamycin after the onset of polyposis at 9 months of age. Rapamyc… (full text at CIViC) PMID 18281551 · Wei et al., 2008 · Open in CIViC	civic
STK11 Loss	Sirolimus	Predictive	D	Supports Sensitivity Response	1	accepted	EID1619 Treatment of mice with a heterozygous loss of Lkb1 (STK11) with rapamycin led to reduction in polyp size (p < 0.0001) and number of polyps (p=0.00022). pS6 staining was also reduced after rapamycin tr… (full text at CIViC) PMID 19541609 · Shackelford et al., 2009 · Open in CIViC	civic